Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,380 result(s) found. Displaying page 2,118 of 2,219.
    «« First « Previous 2114  2115  2116  2117  2118  2119  2120  2121  2122  Next» Last»»
    EudraCT Number: 2015-000051-24 Sponsor Protocol Number: RemiPedEntropy_v1.0 Start Date*: 2015-03-26
    Sponsor Name:Klaus Olkkola/University of Helsinki
    Full Title: The pharmacokinetics and –genomics of remifentanil, and its effects on the depth-of-anaesthesia monitors and the protein synthesis in children.
    Medical condition: otherwise healthy patients undergoing an operation necessitating general anaesthesia
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000605-84 Sponsor Protocol Number: XPORT-DLBCL-030 Start Date*: 2020-09-16
    Sponsor Name:Karyopharm Therapeutics Inc.
    Full Title: A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DL...
    Medical condition: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) FR (Ongoing) IT (Trial now transitioned) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000748-16 Sponsor Protocol Number: MT-2-01 Start Date*: 2017-09-14
    Sponsor Name:Minoryx Therapeutics S.L.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTINATIONAL, MULTICENTER STUDY WITH OPEN-LABEL TREATMENT EXTENSION TO ASSESS THE EFFECT OF MIN-102 ON THE PROGRESSION OF ADRENOMYELONEUROPATHY IN M...
    Medical condition: ADRENOMYELONEUROPATHY IN MALE PATIENTS WITH X-LINKED ADRENOLEUKODYSTROPHY
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) ES (Ongoing) NL (Completed) PL (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004755-17 Sponsor Protocol Number: MYST-FACT Start Date*: 2024-10-01
    Sponsor Name:FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
    Full Title: PHASE I/II CLINICAL TRIAL OF ALLOGENEIC BONE MARROW DERIVED MESENCHYMAL STROMAL CELL THERAPY FOR THE PREVENTION AND TREATMENT OF PULMONARY FIBROSIS SECONDARY TO POST-INFECTIVE ARDS OR ALLOIMMUNE RE...
    Medical condition: PULMONARY FIBROSIS SECONDARY TO ARDS OR ALLOIMMUNE REACTION AFTER TRANSPLANTATION
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10022619 Interstitial pulmonary fibrosis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021253-39 Sponsor Protocol Number: SAKK35/10 Start Date*: 2011-12-16
    Sponsor Name:Swiss Group for Clinical Cancer Research SAKK
    Full Title: Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy. A randomized, open-label, multicentre phase II trial.
    Medical condition: Untreated patients with follicular lymphoma in need of therapy.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025310 Lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) DK (Prematurely Ended) FI (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002813-33 Sponsor Protocol Number: ARMYDA-9DAPAtrial Start Date*: 2023-02-21
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA
    Full Title: Early use of dapaglifozin in diabetic patients with acute myocardial infarction and reduced ejection fraction: the randomized ARMYDA-9 DAPA trial
    Medical condition: Patients with type 2 diabetes and ST-elevation myocardial infarction treated with primary primary percutaneous coronary intervention and reduced left ventricle ejection fraction.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10064346 STEMI LLT
    20.0 100000004849 10011949 Decompensation cardiac LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003362-41 Sponsor Protocol Number: Leuk-CTL-001 Start Date*: 2020-09-23
    Sponsor Name:FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
    Full Title: Phase I/IIa clinical trial on the safety and preliminary efficacy of donor-derived anti-leukemia cytotoxic T lymphocytes for the prevention of leukemia relapse in children given haploidentical hema...
    Medical condition: Leukemia relapse prevention given haploidentical hematopoietic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000558-37 Sponsor Protocol Number: ARQ092-103 Start Date*: 2017-02-22
    Sponsor Name:ArQule, Inc.
    Full Title: A Phase 1/2 Study of ARQ 092 in Patients with Overgrowth Diseases and Vascular Anomalies with Genetic Alterations of the PI3K/AKT Pathway
    Medical condition: subjects (at least 6 years) suffering from diseases overgrowth and vascular anomalies with genetic alterations of the PI3K / AKT pathway.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) FR (Completed) ES (Temporarily Halted) GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003651-42 Sponsor Protocol Number: AVT06-GL-C01 Start Date*: 2022-04-14
    Sponsor Name:Alvotech Swiss AG
    Full Title: A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT06 Compared with EU-Eylea® in Subjects with Neovascular (wet) Age related Macular D...
    Medical condition: Neovascular (wet) Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) SK (Completed) CZ (Completed) HU (Completed) BG (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005071-40 Sponsor Protocol Number: AVT03-GL-C01 Start Date*: 2022-10-31
    Sponsor Name:Alvotech Swiss AG
    Full Title: A Randomized, Double-Blind, Parallel Design, Repeat Dose, 2-arm, Multicenter Study Comparing the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profiles of AVT03 and US-Prolia® in Postmenopa...
    Medical condition: Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031282 Osteoporosis PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002161-56 Sponsor Protocol Number: NeM-CSM-FT-01 Start Date*: 2017-04-13
    Sponsor Name:Mateusz Gola
    Full Title: Towards the understanding of neuronal mechanisms of compulsive sexual behaviors - pharmacotherapy
    Medical condition: compulsive sexual behavior (hypersexual disorder)
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011181-28 Sponsor Protocol Number: SP954 Start Date*: 2009-11-02
    Sponsor Name:Schwartz Biosciences, INC - UCB Group
    Full Title: An open-label, multicenter, multinational study of lacosamide as first add-on anti epileptic drug (AED) treatment in subjects with partial onset seizures. ESTUDIO ABIERTO, MULTICÉNTRICO Y MULTINACI...
    Medical condition: Epilepsy / Epilepsia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015037 Epilepsy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) FI (Completed) IT (Completed) PL (Completed) NL (Prematurely Ended) BG (Completed) FR (Completed) GR (Completed) HU (Completed) PT (Prematurely Ended) DE (Completed) CZ (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-002370-39 Sponsor Protocol Number: ALXN1210-PNH-303 Start Date*: 2019-07-02
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label, Pharmacokinetic, Noninferiority Study of Ravulizumab Administered Subcutaneously Versus Intravenously in Adult Patients With Paroxys...
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) NL (Ongoing) SE (Completed) FI (Completed) CZ (Completed) ES (Ongoing) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002134-23 Sponsor Protocol Number: LPS15023 Start Date*: 2018-11-19
    Sponsor Name:sanofi-aventis groupe
    Full Title: Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients with Moderate to Severe Asthma who Completed the TRAVERSE-LTS12551Clinical Trial
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) DE (Completed) NL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001976-48 Sponsor Protocol Number: IM011023 Start Date*: 2018-08-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    20.0 10017947 - Gastrointestinal disorders 10011398 Crohn's LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) FR (Completed) ES (Ongoing) PL (Completed) DE (Completed) DK (Prematurely Ended) PT (Completed) NL (Completed) BE (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-002054-37 Sponsor Protocol Number: 1000053649 Start Date*: 2019-09-18
    Sponsor Name:Hospital for Sick Children
    Full Title: Pilot Study of Nivolumab in Pediatric Patients with Hypermutant Cancers
    Medical condition: HYPERMUTANT CANCERS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10078672 DNA mismatch repair protein gene mutation PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038111 Recurrent cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070308 Refractory cancer PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-002038-21 Sponsor Protocol Number: CO40115 Start Date*: 2018-05-01
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC TRIPLE-NEGATI...
    Medical condition: Triple-negative breast cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003797-23 Sponsor Protocol Number: KKS-305 Start Date*: 2023-05-16
    Sponsor Name:Philipps University Marburg
    Full Title: Myeloperoxidase inhibition in patients with ischemic or non-ischemic cardiomyopathy and heart failure with reduced ejection fraction
    Medical condition: Ischemic or non-ischemic cardiomyopathy and heart failure with reduced ejection fraction. Danke
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007554 Cardiac failure PT
    27.0 10007541 - Cardiac disorders 10078289 Heart failure with reduced ejection fraction PT
    20.0 10007541 - Cardiac disorders 10055222 Non-ischemic cardiomyopathy LLT
    20.0 10007541 - Cardiac disorders 10055217 Ischemic cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003066-24 Sponsor Protocol Number: MW2012-01-01 Start Date*: 2014-12-17
    Sponsor Name:MediWound Ltd.
    Full Title: A multicenter, multinational, randomized, controlled, open label study, performed in children with thermal burns, to evaluate the efficacy and safety of NexoBrid as compared to standard of care (SO...
    Medical condition: The study objective is to evaluate the safety and clinical benefit of NexoBrid in hospitalized children (0-18 years) with deep partial and/or full thickness thermal burns of 1-30% TBSA and to compa...
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004863 10043418 Thermal burns HLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) SK (Completed) DE (Completed) BE (Completed) AT (Prematurely Ended) BG (Prematurely Ended) NL (Prematurely Ended) FR (Completed) SE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002242-36 Sponsor Protocol Number: GB001-2001 Start Date*: 2018-12-06
    Sponsor Name:GB001, Inc.
    Full Title: A Phase 2b, randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 as maintenance therapy in adult subjects with moderate to sev...
    Medical condition: Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) BE (Completed) AT (Completed) ES (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2114  2115  2116  2117  2118  2119  2120  2121  2122  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Feb 10 12:48:16 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA